Company profile

Edward A. Pesicka
Incorporated in
Fiscal year end
Former names
O&m Holding Inc, Owens & Minor Inc
IRS number

OMI stock data

FINRA relative short interest over last month (20 trading days) ?


4 Mar 20
4 Apr 20
31 Dec 20


Company financial data Financial data

Quarter (USD) Dec 19 Sep 19 Jun 19 Mar 19
Revenue 1.87B 2.4B 2.48B 2.46B
Net income -39.02M 1.22M -10.48M -14.1M
Diluted EPS -0.64 0.02 -0.18 -0.23
Net profit margin -2.09% 0.05% -0.42% -0.57%
Operating income 17M 25.31M 16.14M 14.69M
Net change in cash -29.77M 5.46M 16.1M 8.93M
Cash on hand 67.03M 96.8M 91.34M 75.24M
Cost of revenue 1.83B 2.04B 2.12B 2.1B
Annual (USD) Dec 19 Dec 18 Dec 17 Dec 16
Revenue 9.21B 9.42B 9.32B 9.72B
Net income -62.37M -437.01M 72.79M 108.79M
Diluted EPS -1.03 -7.28 1.2 1.76
Net profit margin -0.68% -4.64% 0.78% 1.12%
Operating income 73.15M -352.35M 89.25M 199.6M
Net change in cash 722K -38.21M -80.97M 24.47M
Cash on hand 67.03M 66.31M 104.52M 185.49M
Cost of revenue 8.08B 8.35B 8.15B 8.54B

Financial data from company earnings reports

Date Owner Security Transaction Code $Price #Shares $Value #Remaining
31 Mar 20 Mark F Mcgettrick Phantom Stock Common Stock Grant Aquire A 9.15 13 118.95 81,158
31 Mar 20 Robert J Henkel Phantom Stock Common Stock Grant Aquire A 9.15 1 9.15 17,695
31 Mar 20 Moore Eddie N JR Phantom Stock Common Stock Grant Aquire A 9.15 8 73.2 28,799
26 Mar 20 Shana Carol Neal Common Stock Payment of exercise Dispose F 5.65 1,978 11.18K 60,409
9 Mar 20 Edward A Pesicka Common Stock Payment of exercise Dispose F 5.61 43,787 245.65K 384,479
90.3% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 181 176 +2.8%
Opened positions 29 32 -9.4%
Closed positions 24 24
Increased positions 63 51 +23.5%
Reduced positions 55 55
13F shares
Current Prev Q Change
Total value 1.13B 996.23M +13.3%
Total shares 56.94M 55.37M +2.8%
Total puts 315.2K 756.1K -58.3%
Total calls 678.1K 288.4K +135.1%
Total put/call ratio 0.5 2.6 -82.3%
Largest owners
Shares Value Change
BLK BlackRock 10.01M $51.75M +4.5%
Vanguard 5.29M $27.36M +3.9%
JPM JPMorgan Chase & Co. 5.16M $26.67M +8.0%
Dimensional Fund Advisors 5.05M $26.09M -0.0%
STT State Street 2.71M $14.03M +20.7%
Renaissance Technologies 2.49M $12.89M +99.0%
Royce & Associates 2.13M $11.04M +6.1%
LSV Asset Management 1.72M $8.91M +32.6%
IVZ Invesco 1.4M $7.26M -1.3%
Clough Capital Partners L P 1.24M $6.42M +27.0%
Largest transactions
Shares Bought/sold Change
BX Blackstone 0 -1.76M EXIT
Renaissance Technologies 2.49M +1.24M +99.0%
D. E. Shaw & Co. 216.8K -609.78K -73.8%
STT State Street 2.71M +465.1K +20.7%
BLK BlackRock 10.01M +428.48K +4.5%
LSV Asset Management 1.72M +424.19K +32.6%
JPM JPMorgan Chase & Co. 5.16M +382.43K +8.0%
Oxford Asset Management 320.76K +320.76K NEW
BK Bank Of New York Mellon 935.99K -313.73K -25.1%
Bridgeway Capital Management 406K +306K +306.0%

Financial report summary

  • We face competition and accelerating pricing pressure.
  • We have significant concentration in and dependence on certain healthcare provider customers and Group Purchasing Organizations.
  • Our operating income is dependent on certain significant domestic suppliers.
  • Our results of operations may suffer upon the bankruptcy, insolvency, or other credit failure of a customer that has a substantial amount owed to us.
  • Changing conditions in the United States healthcare industry may impact our results of operations.
  • We may not be able to generate sufficient cash to service our debt and other obligations.
  • Our credit facilities and our existing notes have restrictive covenants that could limit our financial flexibility.
  • An interruption in the ability of our business to manufacture products may have a material adverse effect on our business.
  • An inability to obtain key components, raw materials or manufactured products from third parties may have a material adverse effect on our Global Products segment.
  • We may incur product liability losses, litigation liability, product recalls, safety alerts or regulatory action associated with the products that we source, assemble, manufacture and sell which can be costly and disruptive to our business.
  • We must obtain clearance or approval from the appropriate regulatory authorities prior to introducing a new product or a modification to an existing product. The regulatory clearance process may result in substantial costs, delays and limitations on the types and uses of products we can bring to market, any of which could have a material adverse effect on our business.
  • Our inability to adequately integrate acquisitions could have a material adverse effect on our operations.
  • Our Global Products segment is exposed to price fluctuations of key commodities, which may negatively impact our results of operations.
  • Our business and operations depend on the proper functioning of critical facilities, supply chain and distribution networks.
  • Our investment in Fusion5 may continue to incur losses.
  • We are subject to stringent regulatory and licensing requirements.
  • Compliance with the terms and conditions of Byram’s Corporate Integrity Agreement requires significant resources and, if we fail to comply, we could be subject to penalties or excluded from participation in government healthcare programs, which could seriously harm our results of operations, liquidity and financial condition.
  • General economic conditions may adversely affect demand for our products and services.
  • We operate within the European Union and therefore may be affected by the United Kingdom's withdrawal from the European Union.
  • Our continued success is substantially dependent on positive perceptions of our reputation.
  • We may experience competition from third-party online commerce sites.
  • Audits by tax authorities could result in additional tax payments for prior periods, and tax legislation could materially adversely affect our financial results and tax liabilities.
  • Recent significant changes to our executive leadership team and any future loss of members of such team, and the resulting management transitions might harm our future operating results.
  • Our goodwill may become impaired, which would require us to record a significant charge to earnings in accordance with generally accepted accounting principles.
  • The market price for our common stock may be highly volatile.
  • We cannot assure you that the proposed Movianto sale will be completed.
  • We and the Movianto business will be subject to business uncertainties while the sale is pending that could adversely affect our business and the Movianto business.
Management Discussion
  • The decrease in net revenue for the year reflected the impact of lower distribution revenues as a result of customer non-renewals, primarily resulting from service issues prior to early 2019, partially offset by revenue growth in other business lines. The changes from prior year also include an unfavorable impact from foreign currency translation of $5.8 million. Net revenue for Global Products benefited when compared to prior year from the acquisition of Halyard in April 2018. Halyard sales from January through April 2019 were $255 million (net of $71 million of intercompany sales).
  • Cost of goods sold includes the cost of the product (net of supplier incentives and cash discounts) and all costs incurred for shipments of products from manufacturers to our distribution centers for all customer arrangements where we are the primary obligor and bear risk of general and physical inventory loss. These are sometimes referred to as distribution contracts. Cost of goods sold also includes direct and certain indirect labor, material and overhead costs associated with our Global Products business. There is no cost of goods sold associated with our fee-for-service arrangements. Cost of goods sold compared to prior year reflects changes in sales activity, including sales mix. Cost of goods sold when compared to prior year was also impacted from the acquisition of Halyard in April 2018. Halyard cost of goods sold from January through April 2019 were $210 million (net of $72 million of intercompany eliminations).
  • Gross margin for the year reflected strong revenue growth with Byram and overall improved sales mix, as the Global Products revenues constitute a higher percentage of revenue, which was partially offset by unfavorable impact from foreign currency translation of $4.8 million.
Content analysis ?
H.S. freshman Avg
New words: affirmative, Andrew, Bayer, buyer, circumvented, clarify, consent, customary, Deputy, divestiture, Earlier, EHDH, escrow, extinguishment, Fischer, Fisher, French, half, Henkel, implicit, Jeffery, Likewise, noncurrent, outdated, overlapping, Patheon, PNC, principle, publicly, readily, redundant, Reichhold, Relief, reorganization, residual, resignation, Scientific, securitization, Simplification, standby, stepdown, strain, strong, sum, superseded, surfaced, swingline, therefrom, Thermo, TRW, unrealized, withdrew, Wuhan, Zacur
Removed: acting, allocated, Alloga, ambient, American, ArcRoyal, Barbara, Belgium, Bierman, billed, billing, biotechnology, carefully, certified, Colpo, consulting, Czech, decreased, Deferral, delinquent, Deutsche, DHL, disclosing, distinct, diverse, effected, embedded, emergency, EPS, Erika, Essig, Ethicon, exact, expansion, expiring, export, frozen, function, Geoffrey, Gerdelman, Germany, graph, Hill, initiative, internally, ISO, John, Johnson, judgment, Lemuel, macroeconomic, Marlatt, Marsh, Martha, McKesson, medicinal, Medtronic, Merger, minimum, Mongoose, narcotic, negotiating, nonforfeitable, OM, outsourcing, Overview, pack, par, Paul, perpetual, pick, planning, Poland, predictable, preliminary, pursued, Region, remediating, remit, rental, repayment, Republic, repurchased, Resolution, retired, return, secondary, semiannually, settlement, similarly, Slovakia, sourced, Spain, sponsored, substitute, superior, supervision, suspended, Switzerland, titled, transport, trend, uncollected, updated, vacated, West, write